NZ521068A - 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders - Google Patents

2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders

Info

Publication number
NZ521068A
NZ521068A NZ521068A NZ52106801A NZ521068A NZ 521068 A NZ521068 A NZ 521068A NZ 521068 A NZ521068 A NZ 521068A NZ 52106801 A NZ52106801 A NZ 52106801A NZ 521068 A NZ521068 A NZ 521068A
Authority
NZ
New Zealand
Prior art keywords
pyrimidin
thiazol
phenyl
amine
dimethyl
Prior art date
Application number
NZ521068A
Other languages
English (en)
Inventor
Peter Martin Fischer
Shudong Wang
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007636A external-priority patent/GB0007636D0/en
Priority claimed from GB0015117A external-priority patent/GB0015117D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of NZ521068A publication Critical patent/NZ521068A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ521068A 2000-03-29 2001-03-28 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders NZ521068A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007636A GB0007636D0 (en) 2000-03-29 2000-03-29 Anti-cancer compounds
GB0015117A GB0015117D0 (en) 2000-06-20 2000-06-20 Anti-cancer compounds
PCT/GB2001/001423 WO2001072745A1 (en) 2000-03-29 2001-03-28 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders

Publications (1)

Publication Number Publication Date
NZ521068A true NZ521068A (en) 2005-04-29

Family

ID=26243984

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ521068A NZ521068A (en) 2000-03-29 2001-03-28 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders

Country Status (11)

Country Link
US (2) US6531479B2 (enExample)
EP (1) EP1274705A1 (enExample)
JP (1) JP5074653B2 (enExample)
CN (1) CN100355751C (enExample)
AU (2) AU4262901A (enExample)
CA (1) CA2401748A1 (enExample)
GB (1) GB2361236B (enExample)
HU (1) HUP0300382A3 (enExample)
IL (1) IL151946A0 (enExample)
NZ (1) NZ521068A (enExample)
WO (1) WO2001072745A1 (enExample)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
US7870013B1 (en) * 2001-06-29 2011-01-11 Versata Development Group, Inc. Automated system and method for managing goals
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
MXPA04002914A (es) * 2001-09-28 2005-06-20 Cyclacel Ltd N- (4- (4-metiltiazol-5-il)pirimidin-2-il) -n-fenilaminas como compuestos antiproliferativos.
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
MXPA04004178A (es) * 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
US20050222054A1 (en) * 2002-03-27 2005-10-06 Cyclacel Limited Combination comprising a CDK inhibitor and doxorubicin
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
AU2003249284A1 (en) * 2002-07-12 2004-02-02 Rigel Pharmaceuticals, Inc. Modulators of cellular proliferation
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
CN1735607B (zh) * 2002-11-21 2010-06-09 诺华疫苗和诊断公司 2,4,6-三取代的嘧啶作为磷脂酰肌醇(pi)3-激酶抑制剂及其在治疗癌症中的应用
JP4673218B2 (ja) * 2002-11-21 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ホスホチジルイノシトール（ｐｉ）３−キナーゼインヒビターとしての２，４，６−三置換ピリミジン、および癌の処置におけるその使用
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
JP2006524688A (ja) * 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
EP1644338A1 (en) * 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
WO2005012298A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
JPWO2005113550A1 (ja) * 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途
WO2006008874A1 (ja) * 2004-05-21 2006-01-26 Banyu Pharmaceutical Co., Ltd. アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
US7858813B2 (en) 2004-08-19 2010-12-28 Dsm Ip Assets B.V. Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products
JP5117189B2 (ja) * 2004-08-27 2013-01-09 サイクラセル リミテッド プリン及びピリミジンｃｄｋ阻害剤、並びに自己免疫疾患の治療のためのそれらの使用
GB0419416D0 (en) * 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US7622486B2 (en) * 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
US20060106013A1 (en) * 2004-10-07 2006-05-18 Boehringer Ingelheim International Gmbh PI3-kinases
CN101083996A (zh) * 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
JP4932735B2 (ja) * 2004-12-17 2012-05-16 アムジエン・インコーポレーテツド アミノピリミジン化合物および使用方法
TWI427077B (zh) 2004-12-30 2014-02-21 Astex Therapeutics Ltd 吡唑化合物及其用途和含有彼之藥學組成物
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
RU2363699C2 (ru) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. Новое производное аминопиридина с ингибиторной активностью в отношении syk.
EP1910874A4 (en) * 2005-08-03 2009-08-05 Corning Inc FAR-UV UV TELECENTRY IMAGING SYSTEM WITH AXISYMETRIC BIREFRINGENT ELEMENT AND POLAR ORTHOGONAL POLARIZATION
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
EP2137165B1 (en) 2007-04-24 2013-04-24 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
ES2539518T3 (es) * 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物およびそれらの使用方法
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
TWI623531B (zh) 2012-11-21 2018-05-11 Ｐｔｃ治療公司 經取代反向嘧啶ｂｍｉ－１抑制劑
KR20150131224A (ko) 2013-03-14 2015-11-24 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
ES2733929T3 (es) 2013-07-12 2019-12-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
JP6524094B2 (ja) * 2013-08-30 2019-06-05 ピーティーシー セラピューティクス， インコーポレイテッド 置換ピリミジンＢｍｉ−１阻害剤
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
WO2015154038A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10479785B2 (en) * 2015-08-04 2019-11-19 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
EP3423437A4 (en) 2016-03-01 2019-07-24 Propellon Therapeutics Inc. INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
AU2017226004B2 (en) * 2016-03-01 2021-07-22 Propellon Therapeutics Inc. Inhibitors of WDR5 protein-protein binding
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
CN108727363B (zh) * 2017-04-19 2020-06-19 劲方医药科技(上海)有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
JP7693656B2 (ja) 2019-10-11 2025-06-17 インサイト・コーポレイション Ｃｄｋ２阻害剤としての二環式アミン
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20240018136A1 (en) * 2022-03-09 2024-01-18 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
JP2025509886A (ja) 2022-03-28 2025-04-11 ニカング セラピューティクス， インコーポレイテッド サイクリン依存性キナーゼ２阻害剤としてのスルホンアミド誘導体
WO2025007859A1 (en) * 2023-07-03 2025-01-09 Insilico Medicine Ip Limited Substituted thiazole compounds as cdk2/4/6 inhibitors and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
DE3751742T3 (de) 1986-01-13 2002-11-21 American Cyanamid Co., Wayne 4,5,6-Substituierte 2-Pyrimidinamine
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JPH08503971A (ja) * 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
KR960704855A (ko) 1993-10-12 1996-10-09 돈 엠. 커. 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof)
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen

Also Published As

Publication number Publication date
IL151946A0 (en) 2003-04-10
HUP0300382A2 (hu) 2003-06-28
AU2001242629B2 (en) 2005-08-11
US6699854B2 (en) 2004-03-02
EP1274705A1 (en) 2003-01-15
CN1420884A (zh) 2003-05-28
GB2361236B (en) 2002-04-24
AU4262901A (en) 2001-10-08
JP5074653B2 (ja) 2012-11-14
US6531479B2 (en) 2003-03-11
CN100355751C (zh) 2007-12-19
US20030149057A1 (en) 2003-08-07
HUP0300382A3 (en) 2006-11-28
JP2003528872A (ja) 2003-09-30
GB2361236A (en) 2001-10-17
WO2001072745A1 (en) 2001-10-04
CA2401748A1 (en) 2001-10-04
US20020019404A1 (en) 2002-02-14
GB0107758D0 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
AU2001242629B2 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
AU2001242629A1 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
AU2004255924B8 (en) Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
JP4495963B2 (ja) 抗増殖性化合物としてのｎ−（４−（４−メチルチアゾール−５−イル）ピリミジン−２−イル）−ｎ−フェニルアミン類
US7262202B2 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
US20050288307A1 (en) Anti-viral compounds
CA2533474A1 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
AU2002249389A1 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
AU2002327968A1 (en) N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -N-phenylamines as antiproliferative compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)